Cargando…

Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action

Purpose: The present work endeavors to report a systematic approach of developing the lipidic self-nanoemulsifying formulation of olmesartan medoxomil (OMT) on the principles of Quality by Design (QbD). Methods: For preparing the self-nanoemulsifying formulation, a mixture of oil, surfactant and cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Arun, Jagdish Kumar, Vodeti, Rajeshwar, Shrivastava, Birendra, Bakshi, Vasudha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335990/
https://www.ncbi.nlm.nih.gov/pubmed/32665896
http://dx.doi.org/10.34172/apb.2020.046
_version_ 1783554232772722688
author Arun, Jagdish Kumar
Vodeti, Rajeshwar
Shrivastava, Birendra
Bakshi, Vasudha
author_facet Arun, Jagdish Kumar
Vodeti, Rajeshwar
Shrivastava, Birendra
Bakshi, Vasudha
author_sort Arun, Jagdish Kumar
collection PubMed
description Purpose: The present work endeavors to report a systematic approach of developing the lipidic self-nanoemulsifying formulation of olmesartan medoxomil (OMT) on the principles of Quality by Design (QbD). Methods: For preparing the self-nanoemulsifying formulation, a mixture of oil, surfactant and cosurfactant were used as vehicles. The excipients were selected after screening by solubility as well as pseudoternary phase titration studies. Mixture design was adopted for systematic optimization of the composition of nanolipidic formulations, which were evaluated for smaller globule size, stable zeta potential and lower values of polydispersity index. The optimized liquid self-nanoemulsifying formulation was identified using numerical and graphical optimization techniques, followed by validation of the experimental model. Solidification of self-nanoemulsifying formulation was carried out using porous carriers, and then optimized on the basis of oil adsorption potential, powder flow property and drug release performance. Pharmacokinetic study was performed in male Wistar rats for evaluating the drug absorption parameters. All the experimental data obtained were subjected to statistical analysis using oneway ANOVA followed by post hoc analysis using Student’s t test. Results: The optimized liquid self-nanoemulsifying formulation showed globule size <100 nm, emulsification efficiency <5 minutes andin vitro drug release >85% within in 30 minutes. Further, the solid SNEDDS formulation was effectively formulated using Neusilin US2 with maximum oil adsorption capacity and good micromeritic properties. Pharmacokinetic evaluation indicated 4 to 5-folds increase (P <0.05) in the values of C(max), AUC, and reduction in T(max) from the nanoformulations vis-à-vis the marketed formulation. Conclusion: Overall, the developed nanolipidic formulation of olmesartan indicated superior efficacy in augmenting the drug dissolution and absorption performance.
format Online
Article
Text
id pubmed-7335990
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-73359902020-07-13 Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action Arun, Jagdish Kumar Vodeti, Rajeshwar Shrivastava, Birendra Bakshi, Vasudha Adv Pharm Bull Research Article Purpose: The present work endeavors to report a systematic approach of developing the lipidic self-nanoemulsifying formulation of olmesartan medoxomil (OMT) on the principles of Quality by Design (QbD). Methods: For preparing the self-nanoemulsifying formulation, a mixture of oil, surfactant and cosurfactant were used as vehicles. The excipients were selected after screening by solubility as well as pseudoternary phase titration studies. Mixture design was adopted for systematic optimization of the composition of nanolipidic formulations, which were evaluated for smaller globule size, stable zeta potential and lower values of polydispersity index. The optimized liquid self-nanoemulsifying formulation was identified using numerical and graphical optimization techniques, followed by validation of the experimental model. Solidification of self-nanoemulsifying formulation was carried out using porous carriers, and then optimized on the basis of oil adsorption potential, powder flow property and drug release performance. Pharmacokinetic study was performed in male Wistar rats for evaluating the drug absorption parameters. All the experimental data obtained were subjected to statistical analysis using oneway ANOVA followed by post hoc analysis using Student’s t test. Results: The optimized liquid self-nanoemulsifying formulation showed globule size <100 nm, emulsification efficiency <5 minutes andin vitro drug release >85% within in 30 minutes. Further, the solid SNEDDS formulation was effectively formulated using Neusilin US2 with maximum oil adsorption capacity and good micromeritic properties. Pharmacokinetic evaluation indicated 4 to 5-folds increase (P <0.05) in the values of C(max), AUC, and reduction in T(max) from the nanoformulations vis-à-vis the marketed formulation. Conclusion: Overall, the developed nanolipidic formulation of olmesartan indicated superior efficacy in augmenting the drug dissolution and absorption performance. Tabriz University of Medical Sciences 2020-07 2020-05-11 /pmc/articles/PMC7335990/ /pubmed/32665896 http://dx.doi.org/10.34172/apb.2020.046 Text en © 2020 The Authors. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
spellingShingle Research Article
Arun, Jagdish Kumar
Vodeti, Rajeshwar
Shrivastava, Birendra
Bakshi, Vasudha
Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title_full Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title_fullStr Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title_full_unstemmed Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title_short Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
title_sort integrated quality by design approach for developing nanolipidic drug delivery systems of olmesartan medoxomil with enhanced antihypertensive action
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335990/
https://www.ncbi.nlm.nih.gov/pubmed/32665896
http://dx.doi.org/10.34172/apb.2020.046
work_keys_str_mv AT arunjagdishkumar integratedqualitybydesignapproachfordevelopingnanolipidicdrugdeliverysystemsofolmesartanmedoxomilwithenhancedantihypertensiveaction
AT vodetirajeshwar integratedqualitybydesignapproachfordevelopingnanolipidicdrugdeliverysystemsofolmesartanmedoxomilwithenhancedantihypertensiveaction
AT shrivastavabirendra integratedqualitybydesignapproachfordevelopingnanolipidicdrugdeliverysystemsofolmesartanmedoxomilwithenhancedantihypertensiveaction
AT bakshivasudha integratedqualitybydesignapproachfordevelopingnanolipidicdrugdeliverysystemsofolmesartanmedoxomilwithenhancedantihypertensiveaction